- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Updates from the SAHARA Trial at AAO 2023
Richard Adler, MD, FACS, provides insights on data presented at AA0 2023, from a study comparing results of the ARMOR procedure versus treatment with cyclosporine ophthalmic emulsion 0.05% in patients with dry eye disease.
EP: 1.Navigating Unmet Needs in Dry Eye Disease Therapies
EP: 2.Key Takeaways from Phase 4 Switch Trial Presented at AAO
EP: 3.Real World Benefit Related to Improving Corneal Staining
EP: 4.Overview of Phase 3 Perfluorohexyloctane Studies at AAO 2023
EP: 5.Updates from the SAHARA Trial at AAO 2023
EP: 6.Dual Mechanism Dry Eye Treatment Shows Promise for Symptoms and Compliance
This is a video synopsis/summary of a Post Conference Perspectives featuring Richard Adler, MD.
Adler discusses results from the SAHARA trial evaluating an investigational procedure called Aqueous Retention and Meibomian Gland Outflow Restoration (ARMOR) for dry eye disease. The ARMOR procedure involves debridement, thermal compression, and expression of the meibomian glands in the eyelids to improve meibum quality and reduce tear evaporation.
The SAHARA trial compared ARMOR to Restasis (cyclosporine ophthalmic emulsion 0.05%) for improving tear breakup time (TBUT) and symptoms in evaporative dry eye. TBUT measures tear evaporation rate. The study found ARMOR showed clinically and statistically significant improvements in both TBUT and symptoms compared with Restasis over 12 weeks.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Echocardiographic Assessment Shows Promise as Risk Predictor in PAH
August 29th 2025Close to 40% of patients with right heart failure and pulmonary arterial hypertension (PAH) who remain critically ill and require admittance to the intensive care unit die within 1 year of that hospitalization.
Read More
